FEDERAL COURT OF AUSTRALIA
Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) [2011] FCA 1307
Citation: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) [2011] FCA 1307 Parties: SANOFI-AVENTIS AUSTRALIA PTY LTD ACN 008 558 807, SANOFI-AVENTIS DEUTSCHLAND GMBH and AVENTISUB II INCORPORATED v APOTEX PTY LTD ACN 096 916 148 File number(s): NSD 1664 of 2008 Judge: JAGOT J Date of judgment: 18 November 2011 Catchwords: COPYRIGHT – construction and effect of amendments introduced by Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth)
CONSUMER LAW – misleading and deceptive conduct – form of declaration relating to threatened misleading and deceptive conduct
DAMAGES – release from undertaking as to damages
PATENTS – form of declaration and injunction regarding threatened patent infringement
PRACTICE AND PROCEDURE – where parties at trial had assumed particular construction of legislation which had yet to commence – whether applicants required leave to re-open case in order to contend for a different construction
STATUTORY INTERPRETATION – Copyright Act 1968 (Cth) s 44BA – meaning of “a work that is product information approved under section 25AA of the Therapeutic Goods Act 1989 in relation to medicine”
Legislation: Acts Interpretation Act 1901 (Cth) ss 15, 15AA, 15AB
Copyright Act 1968 (Cth) ss 10, 44B, 44BA, 47AB, 47B
Therapeutic Goods Act 1989 (Cth) ss 3, 7D, 23, 25, 25A, 25AA
Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth) Sch 1 s 2Cases cited: Autodesk Inc v Dyason (No 2) (1993) 176 CLR 300
Commonwealth v Verwayen (1990) 170 CLR 394
IceTV Pty Ltd v Nine Network Australia Pty Ltd (2009) 239 CLR 458
Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd(No 3) (2011) 92 IPR 320; [2011] FCA 846
University of Wollongong v Metwally (No 2) (1985) 60 ALR 68Date of hearing: 30 September and 10 November 2011 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 54 Counsel for the Applicants: Mr R Cobden SC with Mr C Dimitriadis and Mr A R Lang Solicitor for the Applicants: Jones Day Counsel for the Respondent: Mr D K Catterns QC with Mr N R Murray Solicitor for the Respondent: Freehills
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 1664 of 2008
BETWEEN: SANOFI-AVENTIS AUSTRALIA PTY LTD ACN 008 558 807
First ApplicantSANOFI-AVENTIS DEUTSCHLAND GMBH
Second ApplicantAVENTISUB II INCORPORATED
Third ApplicantAND: APOTEX PTY LTD ACN 096 916 148
Respondent
JUDGE:
JAGOT J
DATE OF ORDER:
18 NOVEMBER 2011
WHERE MADE:
SYDNEY
THE COURT DECLARES THAT:
1.The Respondent/Cross-Claimant has infringed the copyright in version B and version 19 of the Arava product information (together, the Arava Pl) and the Arava Summary of Product Characteristics (Arava SPC) by, prior to 28 May 2011, reproducing in a material form a substantial part of each of those works in the form of the product information for the Respondent/Cross-Claimant’s leflunomide-containing products approved by the Therapeutic Goods Administration in July 2008 (the approved Apotex Pl
Keep reading for free
Create a free CaseChat account to read Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 4) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] FCA 1307
- Decision Date
CaseChat Overview and Summary
The court first examined the impact of the amendment Act on the copyright infringement claim. The amendment Act, which came into effect after the hearing but before the principal judgment, was assumed by both parties to negate any breach of copyright in respect of the works on which Sanofi-Aventis relied. However, Sanofi-Aventis later contended that the amendment Act operated differently than previously assumed, particularly concerning the SPC. The court held that the SPC, in part, constituted product information as approved, and thus, the provisions of the amendment Act exempted the proposed future acts from copyright infringement. Consequently, Sanofi-Aventis was not entitled to any relief for copyright infringement post the commencement of the amendment Act.
The court also addressed the necessity of additional declarations regarding threatened infringements and misleading conduct. Sanofi-Aventis sought declarations to reflect the findings of the principal judgment, while Apotex argued that such declarations were unnecessary. The court found that the declarations were necessary to clarify the legal position and should be consistent with the terms of the patent injunction.
Finally, the court considered the release of the undertaking as to damages. Apotex opposed the release on the basis that Sanofi-Aventis did not disavow the potential argument that the release of the undertaking might deprive Apotex of its benefit should it succeed in its anticipated appeal. The court decided that for abundant caution, the release of the undertaking should be qualified to specify its effective date and avoid any confusion regarding its implications.
The court's reasoning led to specific orders, including the denial of relief for copyright infringement post the amendment Act, the qualification of the release of the undertaking as to damages, and the necessity of additional declarations to reflect the court's findings. These decisions provided clarity and finality to the legal issues raised in the case, ensuring that the parties understood the implications of the court's rulings.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
The SPC, in part, is product information as approved. The part of the SPC that is product information as approved is the part which enabled Sanofi-Aventis to contend that in reproducing the Arava PI version 21 (the most recently approved PI for Arava) Apotex also indirectly reproduced a substantial part of the SPC and thus infringed Sanofi-Aventis’s copyright in the SPC (as found at [360] of the principal judgment). The fact that the SPC, in part, is product information as approved – and that I am satisfied that this part is itself a work in which copyright subsists – is sufficient to engage ss 44BA(1) and (2) of the Copyright Act. The acts proposed to be carried out in the future by Sanofi-Aventis are within the scope of the exemption created by those provisions. It follows that Sanofi-Aventis is not entitled to any relief in respect of infringement of copyright after the commencement of the amendment Act on 28 May 2011. ADDITIONAL DECLARATIONS Sanofi-Aventis claims that declarations should be made in respect of Apotex’s threatened infringements of the patent and threatened misleading and deceptive conduct. Apotex opposes the making of those declarations on the basis that, by reason of the substantive orders, they are unnecessary. As Sanofi-Aventis submitted, the declarations reflect the findings at [274] and [282] of the principal judgment as follows:[274]Apotex has not established that the claim of the patent is invalid. Sanofi-Aventis has established that Apotex’s proposed supply of Apotex’s leflunomide product for the treatment of PsA will infringe the patent. Sanofi-Aventis is thus entitled to declarations and an injunction generally in accordance with paras 14 to 16 of the amended application.[…][282]For these reasons Sanofi-Aventis has established a proper basis for the making of declarations and injunctions to the general effect of those in paras 19-21 of the amended application (albeit not by reference to all of the representations on which it relied). The terms of the declarations are also in dispute. In respect of the declarations relating to threatened infringement of the patent, the same issues arise as in relation to the injunction. I deal with this aspect of the dispute below in the context of the injunction and on the basis that the declaration and injunction, insofar as possible, should be consistent. In respect of the declaration relating to the threatened misleading and deceptive conduct, I agree with Apotex’s position that it is unnecessary to record the specific representations which I found would be made by the threatened conduct and would be misleading and deceptive if made. Otherwise, the identification of the relevant conduct in this declaration also should be consistent with the terms of the patent injunction. RELEASE OF THE UNDERTAKING AS TO DAMAGES Apotex opposed the release of Sanofi-Aventis from the undertaking as to damages given on 30 October 2008 in respect of the interlocutory injunction. As the undertaking relates to the interlocutory injunction (which will be discharged on the making of the final injunction in Sanofi-Aventis’s favour), the undertaking must be released. Apotex’s concern is that Sanofi-Aventis has not disavowed the possibility that it might argue that the effect of the release of the undertaking is to deprive Apotex of its benefit should Apotex succeed in its foreshadowed appeal. I am not aware of any authority suggesting that this might be the effect of the release of the undertaking (that is, that by releasing the undertaking it will be as if the undertaking had never been given). Nevertheless, Sanofi-Aventis did not disavow the potential argument that is of concern to Apotex. In these circumstances, and for abundant caution, the release of the undertaking should be qualified to make clear that the release operates with effect from the date of the release and not otherwise.THE PATENT INJUNCTION